Orphan Drugs Market 2020 | Global Industry Overview, Sales Revenue, Demand and Opportunity 2025

According to IMARC Group’s latest report, titled “Orphan Drugs Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025,”. Looking forward, IMARC Group expects the global orphan drugs market to exhibit moderate growth during the next five years.

Orphan drugs are used to diagnose, prevent, and treat rare medical disorders. These drugs aim to meet particular public health requirements and generally have a limited production, only for a small group of patients. Orphan drugs help in treating several oncological, metabolic, hematologic, immunologic, infectious, and neurological ailments. These ailments majorly include lymphoma, leukemia, cystic fibrosis, glioma, pancreatic cancer, ovarian cancer, etc.

Request for a free sample copy of this report: https://www.imarcgroup.com/orphan-drugs-market/requestsample

Market Trends

The high prevalence of cancer and other rare genetic disorders is primarily driving the need for orphan drugs. Several pharma companies are focusing on developing new orphan drugs for providing personalized therapies for patients. Additionally, the higher approval rate of several pipeline drugs, along with the introduction of numerous favorable government policies to curb the spread of various infectious diseases, is also catalyzing the market growth. Moreover, extensive R&D activities for the development of biological orphan drugs that can treat cancer and minimize the damage caused to the stem cells are further expected to drive the market for orphan drugs in the coming years.

Orphan Drugs Market 2020-2025 Analysis and Segmentation:

The report has segmented the market on the basis of drug type, disease type, phase, top selling drug, distribution channel and region.

Breakup by Drug Type:

  • Biological
  • Non-Biological

Breakup by Disease Type:

  • Oncology
  • Hematology
  • Neurology
  • Cardiovascular
  • Others

Breakup by Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Breakup by Top Selling Drugs:

  • Revlimid
  • Rituxan
  • Copaxone
  • Opdivo
  • Keytruda
  • Imbruvica
  • Avonex
  • Sensipar
  • Soliris
  • Others

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others

Explore full report with table of contents: https://www.imarcgroup.com/orphan-drugs-market

Breakup by Region:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

Key highlights of the report:

  • Market Performance (2014-2019)
  • Market Outlook (2020- 2025)
  • Porter’s Five Forces Analysis
  • Market Drivers and Success Factors
  • SWOT Analysis
  • Value Chain
  • Comprehensive mapping of the competitive landscape

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

Browse Related Report:



About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Media Contact
Company Name: IMARC Group
Contact Person: Elena Anderson
Email: Send Email
Phone: +1 6317911145
Address:30 N Gould St, Ste R
City: Sheridan
State: WY 82801
Country: United States
Website: https://www.imarcgroup.com/

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.